Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Mónica Galli et al.|The Lancet Oncology|2019Cited by 383
Whole-Body MRI Versus PET in Assessment of Multiple Myeloma Disease ActivityConor Shortt, Stephen Eustace, Tadhg G. Gleeson et al.|American Journal of Roentgenology|2009Cited by 184